Add to ORKGPembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab. We present a case of acute kidney injury in a patient on pembrolizumab who was noted to have acute tubulointerstitial nephritis on renal biopsy. Pembrolizumab was discontinued and the patient was started on long-term corticosteroids with a taper. Her renal function improved partially with treatment
Immune checkpoint blockade therapy is gaining popularity among oncologists for treatment of solid an...
International audienceBACKGROUND:Immune Checkpoint Inhibitors (ICPIs) are promising new drugs in tre...
Introduction: Immune checkpoint inhibitors including nivolumab, an antibody against programmed death...
Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcino...
International audienceObjective : Expanded clinical experience with patients treated by pembrolizuma...
Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death protein 1 (PD...
Checkpoint inhibitors are increasingly used to treat different types of malignancy and have been ass...
Immune checkpoint inhibitors (ICPi) have become nowadays one of the most widely prescribed anticance...
Immune checkpoints inhibitors (ICPIs), as either a frontline or adjuvant therapy, showed favorable o...
IntroductionAcute kidney injury (AKI) in cancer patients receiving immune checkpoint inhibitors (ICI...
Background: Immune checkpoint inhibitors are changing the landscape of oncologic treatment as they a...
Abstract Background Acute tubulointerstitial nephritis (ATIN) has been increasingly recognized as an...
Item does not contain fulltextINTRODUCTION: Immune checkpoint inhibitors have taken an important pla...
Background: Pemetrexed (PEM) is a new-generation multitargeted antifolate agent that has been shown ...
The combination of chemotherapy and immune checkpoint inhibition (ICI) therapy is the current standa...
Immune checkpoint blockade therapy is gaining popularity among oncologists for treatment of solid an...
International audienceBACKGROUND:Immune Checkpoint Inhibitors (ICPIs) are promising new drugs in tre...
Introduction: Immune checkpoint inhibitors including nivolumab, an antibody against programmed death...
Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcino...
International audienceObjective : Expanded clinical experience with patients treated by pembrolizuma...
Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death protein 1 (PD...
Checkpoint inhibitors are increasingly used to treat different types of malignancy and have been ass...
Immune checkpoint inhibitors (ICPi) have become nowadays one of the most widely prescribed anticance...
Immune checkpoints inhibitors (ICPIs), as either a frontline or adjuvant therapy, showed favorable o...
IntroductionAcute kidney injury (AKI) in cancer patients receiving immune checkpoint inhibitors (ICI...
Background: Immune checkpoint inhibitors are changing the landscape of oncologic treatment as they a...
Abstract Background Acute tubulointerstitial nephritis (ATIN) has been increasingly recognized as an...
Item does not contain fulltextINTRODUCTION: Immune checkpoint inhibitors have taken an important pla...
Background: Pemetrexed (PEM) is a new-generation multitargeted antifolate agent that has been shown ...
The combination of chemotherapy and immune checkpoint inhibition (ICI) therapy is the current standa...
Immune checkpoint blockade therapy is gaining popularity among oncologists for treatment of solid an...
International audienceBACKGROUND:Immune Checkpoint Inhibitors (ICPIs) are promising new drugs in tre...
Introduction: Immune checkpoint inhibitors including nivolumab, an antibody against programmed death...